XVIVO: TransMedics confirms that the US DCD segment is live and kicking - Redeye

XVIVO’s future competitor in both the US Heart, Lung and Liver segment reported strong growth late yesterday. TransMedics confirms that the US DCD growth remains very high, especially when integrating machine perfusion with integrated advanced services.

Länk till analysen i sin helhet: https://www.redeye.se/research/955952/xvivo-transmedics-confirms-that-the-us-dcd-segment-is-live-and-kicking?utm_source=finwire&utm_medium=RSS